Inhibitor Therapeutics (INTI) POS AM 26 Apr 19 Prospectus update (post-effective amendment) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2018
Document and Entity Information [Abstract]
Document Type	POS AM
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Trading Symbol	HPPI
Entity Registrant Name	HedgePath Pharmaceuticals, Inc.
Entity Central Index Key	0001042418
Entity Filer Category	Non-accelerated Filer

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,108,713	$ 344,113
Prepaid expenses	41,296	61,655
Deposit		250,000
Total current assets	1,150,009	655,768
Other long-term assets	82,992	112,284
Total assets	1,233,001	768,052
Current liabilities:
Accounts payable	384,829	534,956
Dividends payable, related party	99,945
Other liabilities	215,876	66,533
Total current liabilities	700,650	601,489
Deferred revenue, related party	500,000
Total liabilities	1,200,650	601,489
Commitments and contingencies
Stockholders' equity:
Common stock, $0.0001 par value; 500,000,000 shares authorized; 370,084,064 and 369,599,266 shares issued and outstanding in 2018 and 2017, respectively	37,008	36,960
Additional paid-in capital	49,015,120	48,403,523
Accumulated deficit	(52,980,643)	(48,273,920)
Total stockholders' equity	32,351	166,563
Total liabilities and stockholders' equity	1,233,001	768,052
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred stock
Series B Convertible, Redeemable, Preferred Stock [Member]
Stockholders' equity:
Preferred stock	$ 3,960,866

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	2,253,623	2,253,623
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	500,000,000	500,000,000
Common Stock, shares issued	370,084,064	369,599,266
Common Stock, shares outstanding	370,084,064	369,599,266
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Convertible, Redeemable, Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	7,246,377	7,246,377
Preferred stock, shares issued	5,797,102	0
Preferred stock, shares outstanding	5,797,102	0

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues [Abstract]
Total revenues	$ 0	$ 0
Expenses:
Research and development	2,633,567	2,227,589
General and administrative	1,930,690	2,891,442
Total expenses	4,564,257	5,119,031
Loss from operations	(4,564,257)	(5,119,031)
Interest income	14,027	17,866
Net loss	(4,550,230)	(5,101,165)
Preferred stock dividend	(156,493)
Net loss applicable to common shareholders	$ (4,706,723)	$ (5,101,165)
Basic and diluted loss per share	$ (0.01)	$ (0.01)
Weighted average common shares outstanding	369,812,939	366,622,107

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Total	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2016	$ 7,029,962		$ 35,345	$ 50,167,372	$ (43,172,755)
Beginning balance, shares at Dec. 31, 2016			353,447,172
Issuance of common stock upon warrant exercise	49,500		$ 41	49,459
Issuance of common stock upon warrant exercise, shares			412,500
Issuance of common stock in payment of vested restricted stock units, net	(3,677,727)		$ 1,574	(3,679,301)
Issuance of common stock in payment of vested restricted stock units, net, shares			15,739,594
Stock based compensation	1,865,993			1,865,993
Net loss	(5,101,165)				(5,101,165)
Ending balance at Dec. 31, 2017	166,563		$ 36,960	48,403,523	(48,273,920)
Ending balance, shares at Dec. 31, 2017			369,599,266
Sale of Preferred Stock and common stock warrants to related party, net	3,960,866	$ 3,960,866
Sale of Preferred Stock and common stock warrants to related party, Shares		5,797,102
Issuance of common stock upon warrant exercise	12,000		$ 10	11,990
Issuance of common stock upon warrant exercise, shares			100,000
Issuance of common stock for payment of dividends on Preferred Stock	56,547		$ 18	56,529
Issuance of common stock for payment of dividends on Preferred Stock, Shares			184,798
Issuance of common stock in payment of vested restricted stock units, net			$ 13	(13)
Issuance of common stock in payment of vested restricted stock units, net, shares			125,000
Stock based compensation	543,098		$ 7	543,091
Stock based compensation, Shares			75,000
Preferred stock dividends	(156,493)				(156,493)
Net loss	(4,550,230)				(4,550,230)
Ending balance at Dec. 31, 2018	$ 32,351	$ 3,960,866	$ 37,008	$ 49,015,120	$ (52,980,643)
Ending balance, shares at Dec. 31, 2018		5,797,102	370,084,064

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating activities:
Net loss	$ (4,550,230)	$ (5,101,165)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Stock-based compensation	543,098	1,865,993
Changes in assets and liabilities:
Prepaid expenses and other assets	299,651	28,734
Accounts payable and other current liabilities	(785)	293,356
Net cash flows used in operating activities	(3,708,266)	(2,913,082)
Financing activities:
Net settlement in connection with the issuance of shares associated with underlying Restricted Stock Units		(3,677,727)
Advances of royalties, related party	500,000
Proceeds from exercise of common stock warrants	12,000	49,500
Proceeds from the sale of Preferred Stock and common stock warrants, related party, net	3,960,866
Net cash provided by (used in) from financing activities	4,472,866	(3,628,227)
Net increase(decrease) in cash and cash equivalents	764,600	(6,541,309)
Cash and cash equivalents at beginning of year	344,113	6,885,422
Cash and cash equivalents at end of year	1,108,713	344,113
Supplemental disclosure of non-cash financing activities:
Fair value of shares withheld with net settlement transaction		$ 3,677,727
Issuance of common stock for payment of Preferred Stock dividend	56,547
Accrued, but unpaid dividends	$ 99,946

Corporate overview

Corporate overview	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Corporate overview	1. Corporate overview: Overview The accompanying audited financial statements of HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”, “HPPI”, “we”, “us” or similar terminology) as successor to Commonwealth Biotechnologies, Inc., a Virginia corporation (“CBI”), have been prepared by the Company as a going concern, and in accordance with accounting principles generally accepted in the United States of America (“GAAP”). As used herein, the term “common stock” means the Company’s common stock, $0.0001 par value per share. Nature of the Business The Company is a company that is seeking to discover, develop and commercialize innovative therapeutics for patients with certain cancers and certain non-cancerous proliferation disorders. The Company may also explore acquiring or licensing other innovative therapeutics addressing unmet needs and orphan indications beyond cancer. The Company’s current focus is on the development of therapies for lung and prostate cancers in the U.S. market after licensing its initial indication targeting basal cell carcinoma in patients with Basal Cell Carcinoma Nevus Syndrome to Mayne Pharma in December 2018. The Company’s primary proposed therapy is based upon the use of SUBA-Itraconazole, which is a patented, oral formulation of the currently marketed anti-fungal drug itraconazole. The Company demonstrated in its previous Phase 2(b) trial in Basal Cell Carcinoma Nevus Syndrome (“BCCNS”) that the dosing of oral capsules of SUBA-Itraconazole affects the Hedgehog signaling pathway, a major regulator of many fundamental cellular processes, which, in turn, can impact the development and growth of cancers such as basal cell carcinoma. Itraconazole has been approved by the U.S. Food and Drug Administration (“FDA”) for, and has been extensively used to, treat fungal infections and has an extensive history of safe and effective use in humans. The Company has developed, optioned and licensed intellectual property and know-how related to the treatment of cancer patients using itraconazole and certain itraconazole analogues. Overview of December 2018 Transactions with Mayne Pharma On December 17, 2018 (the “Effective Date”), the Company entered into the following related agreements (collectively, the “Transaction Documents”): • An agreement, by and among the Company, and Mayne Pharma, and Mayne Pharma International, an affiliate of Mayne Pharma (the “Agreement”); • The Third Amended and Restated Supply and License Agreement with Mayne Pharma (the “Third Amended SLA”), which amended and restated the Company’s Second Amended and Restated Supply and License Agreement with Mayne Pharma, dated as of May 15, 2015 (as amended immediately prior to the Effective Date, the “Second Amended SLA”); and • Amended and Restated Sublicense Agreement, by and between the Company and Mayne Pharma International, which amends and restates that certain Sublicense Agreement, dated August 31, 2015, between the Company and Mayne Pharma International, as amended. In addition, pursuant to the terms of the Agreement, the Company and Mayne Pharma agreed to vote in favor of the adoption of an Amended and Restated Certificate of Designation (“the Amended and Restated COD”) for the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”), which amended and restated the terms of the Series B Preferred Stock (originally issued to Mayne Pharma on January 8, 2018) to remove the redemption rights of the Series B Preferred Stock as described below. As of the Effective Date and at December 31, 2018, all 5,797,102 outstanding shares the Series B Preferred Stock are held by Mayne Pharma. The Transaction Documents resulted from negotiations regarding the existing right of Mayne Pharma under the Second Amended SLA to elect to assume control of the regulatory and clinical development program for SUBA-Itraconazole for the treatment of BCCNS (such product candidate “SUBA-Itraconazole BCCNS”) in exchange for a royalty on any future net sales of SUBA-Itraconazole BCCNS by Mayne Pharma in the United States if and FDA New Drug Application (“NDA”) was not accepted for filing by FDA by December 31, 2018 (subject to limited extension if the NDA were filed in December 2018). Based on unforeseen requirements imposed by FDA in September 2018, the Company determined that it would be unable to responsibly file the SUBA-Itraconazole BCCNS NDA by this deadline, and thus the Company commenced negotiations with Mayne Pharma to transfer SUBA-Itraconazole BCCNS in advance of December 31, 2018 on negotiated terms deemed beneficial to the Company. December 2018 Agreement with Mayne Pharma Pursuant to the terms of the Agreement, on the Effective Date, Mayne Pharma (in its capacity as the holder of more than 50% of the outstanding voting securities of the Company) executed and delivered to the Company which consented to the taking of the following actions: (a) the adoption of the Amended and Restated COD; (b) the election of each E. Brendan Magrab, W. Mark Watson, Dr. R. Dana Ono, Stefan J. Cross and Robert D. Martin (each a current member of the Board) to serve on the Board for a one-year term that expires at the next annual meeting of the Company’s stockholders or until his earlier death, resignation or removal; and (c) the approval of an increase in the size of the Company’s 2014 Equity Incentive Plan (the “EIP”) by 11,000,000 shares of common stock from 32,583,475 shares to 43,583,475 shares. In addition, pursuant to the Agreement, for the period beginning on the Effective Date and ending three (3) years from the Effective Date, in the event that the Company asks its stockholders (whether at a meeting of stockholders or pursuant to a written consent of stockholders) to vote on or approve a proposal to effect a reverse split of the Company capital stock for the purpose of uplisting the common stock to a U.S. national securities exchange (a “Reverse Stock Split Proposal”), Mayne Pharma (on behalf of itself and its affiliates) agreed to vote or cause to be voted (in person, by proxy or by action by written consent, as applicable) all shares of the Company’s voting capital stock that either Mayne Pharma then owns or over which Mayne Pharma has voting control in favor of the adoption and approval of any such Reverse Stock Split Proposal. No assurances are given that the Company will seek an uplisting to a U.S. national securities exchange or implement a reverse stock split of its common stock. Also, pursuant to the Agreement, Mayne Pharma consented and agreed (under the terms of agreements previously executed with the Company) to an increase in the number of shares of common stock that the Company may issue under the EIP to 17,624,000 shares from the current limit of 6,624,000 shares, with the agreement and understanding that such increase will be utilized by the Company during the period from the Effective Date through December 31, 2021. December 2018 – Third Amended and Restated Supply and License Agreement with Mayne Pharma Pursuant to the Third Amended SLA, as of the Effective Date, Mayne Pharma assumed control of the regulatory and clinical development program for SUBA-Itraconazole BCCNS and immediately assumed responsibility for all expenses related to exploiting the SUBA-Itraconazole product in the BCCNS field, provided that the Company continues to be responsible for all liabilities related to the product in the United States prior to the Effective Date. The Third Amended SLA will continue in effect on an exclusive basis in the on substantially the same terms as were provided for under the Second Amended SLA, except as described below. In consideration of the transfer to Mayne Pharma of the SUBA-Itraconazole BCCNS clinical data and regulatory rights, the Company will receive the following consideration: (a) a 9% quarterly cash royalty (the “Royalty”) on future net sales, if any, of SUBA-Itraconazole product in the BCCNS field in the United States, from which certain royalties owed by the Company to Mayne Pharma for access to certain patents would also be funded. (b) Mayne Pharma’s agreement to advance funds to the Company in an aggregate amount of up to $5 million on the following terms and conditions: (i) As of the Effective Date, Mayne Pharma shall make an Advance to the Company of $500,000; the Company received this first Advance on December 18, 2018; (ii) Within three (3) business days following the completion of the agreed upon activities associated with transferring the SUBA-Itraconazole BCCNS product to Mayne Pharma, Mayne Pharma must make an Advance to the Company of $1 million; (iii) If, and only if, the Company’s Phase 2(b) clinical trial data have been provided to Mayne Pharma in all material respects so as to allow Mayne Pharma to assume control of SUBA-Itraconazole BCCNS in the United States, upon the earlier of June 30, 2019 or the acceptance for filing by FDA of an NDA for the SUBA-Itraconazole BCCNS, Mayne Pharma must make an Advance to the Company of $1,500,000; and (iv) If the Company raises aggregate gross proceeds of more than $ Series B Preferred Stock held by Mayne Pharma or warrants to third parties in one or more equity financings by June 30, 2021 (the “Equity Funding Achievement”), the Company may request additional Advances of up to an amount equal to $2 million less the amount of aggregate gross proceeds received by from Mayne Pharma from the sale of New Securities if Mayne Pharma elects to participate in such equity financings pursuant to contractual pro rata participation rights contained in the Third Amended SLA. (c) The field covered by the Third Amended SLA was amended to specifically include only the following indications: (i) any prostate cancer, prostatic intraepithelial neoplasia and benign prostatic hyperplasia, (ii) any lung cancer and atypical adenomatous hyperplasia, and (iii) familial adenomatous polyposis, colorectal polyps and Barett’s esophagus (the “Field”). The Company’s work on these indications will no longer be tied to the achievement of clinical or commercial target dates as they were under the Second Amended SLA. (d) Mayne Pharma will continue to provide quantities of SUBA- Itraconazole drug and placebo oral capsules without charge for the Company’s SUBA-Itraconazole Prostate clinical studies and for future indications as agreed to by the parties. (e) Pursuant to the Third Amended SLA, Mayne Pharma has licensed to the Company the right to use all pre-clinical or clinical trial or other data generated or owned by Mayne Pharma related to SUBA- Itraconazole anywhere in the world for its activities under the Third Amended SLA. With respect to each Advance made by Mayne Pharma prior to the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.75 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company, and with respect to each Advance made by Mayne Pharma following the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.85 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company. 70 December 2018 Amended and Restated Sublicense Agreement The Amended and Restated Sublicense Agreement amends and replaces a similar agreement entered into between the Company and Mayne Pharma International, dated as of May 15, 2015, under which Mayne Pharma International sublicensed to the Company the exclusive U.S. rights to two certain third-party patents relating to the use of itraconazole as a treatment for cancer and age-related macular degeneration. The Amended and Restated Sublicense Agreement amends the required payments to Mayne Pharma for certain development-related milestone payments related to SUBA-Itraconazole BCCNS and allows for the termination of the Amended and Restated Sublicense Agreement if the Third Amended SLA expires or is terminated. January Series B Preferred Stock Purchase Agreement On January 8, 2018, the Company entered into Purchase Agreement with Mayne Pharma , pursuant to which Mayne Pharma agreed to purchase from the Company, and the Company agreed to issue to Mayne Pharma (over three closings as described further below): (i) up to 7,246,377 shares of the Company’s then newly designed Series B Preferred Stock at $0.69 per share of Series B Preferred Stock (with each share of Series B Preferred Stock being convertible into three (3) shares of the Company’s common stock for an effective price per share of common stock of $0.23), for potential gross proceeds of $5,000,000; (ii) Series A Warrants to purchase up to an aggregate 5,434,783 shares of common stock, with a two-year term from the date of issuance and an exercise price per share of $0.23; and (iii) Series B Warrants to purchase up to an aggregate of 5,434,783 shares of common stock, with a five-year term from the date of issuance and an exercise price per share of $0.275 (together with the Series A Warrants, the “Warrants”). The transactions contemplated by the Purchase Agreement are referred to herein as the “Financing.” The Financing contemplated three closings (each, a “Closing”), as follows: (i) $2.4 million was funded at an initial closing of the Financing that occurred on January 10, 2018 (the “Initial Closing”); (ii) $1.6 million was funded in July 2018 (the “Second Closing”); and (iii) $1.0 million that was to be funded on or before December 31, 2018 (or the “Third Closing”) did not occur. The funding of the Third Closing was conditioned upon the acceptance of filing by the FDA of the Company’s NDA for SUBA-Itraconazole BCCNS, which did not occur. Terms of the Series B Preferred Stock The Series B Preferred Stock carries the following provisions: Price Per Share . The purchase price for each share of Series B Preferred Stock was $0.69 (which is equal to three times (3x) the Conversion Price (as defined below)) (the “Per Share Price”). An applicable number of shares of Series B Preferred Stock was issued at the Initial and Second Closing based on the Per Share Price. Dividends . The shares of Series B Preferred Stock accrue dividends at a rate of 5% of the Per Share Price per annum per share. Dividends are paid se mi-annually Voluntary and Mandatory Conversion . The shares of Series B Preferred Stock issued with the Initial and Second Closing will be convertible as provided for below into an aggregate of 17,391,306 shares of common stock based on a conversion price per share of $0.23 (the “Conversion Price”). Each share of Series B Preferred Stock is convertible into three (3) shares of common stock at any time at the election of Mayne Pharma at a price per share equal to the Conversion Price. The Conversion Price is subject to customary stock-based, but not price-based, anti-dilution protection. Each share of Series B Preferred Stock automatically converts into three (3) shares of common stock based on the Conversion Price upon the approval by the FDA of an NDA for any SUBA-based therapeutic under the Third Amended SLA, pursuant to the Amended and Restated COD. Liquidation Preference . In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, Mayne Pharma (with respect to its holdings of Series B Preferred Stock only) will be entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment will be made to the holders of all other capital stock of the Company (including the common stock) an amount per share of Series B Preferred Stock equal to the Per Share Price plus any dividends accrued but unpaid thereon. Seniority . So long as the shares of Series B Preferred Stock are outstanding, the Company shall not, without the prior written approval of from the holders of a majority of the then outstanding shares of Series B Preferred Stock: (i) establish any security nor incur any secured or unsecured indebtedness (other than trade debt in the ordinary course of business) or (ii) establish and security that is pari passu or senior (or reclassify any junior security so as to make it pari passu or senior) in liquidation preference or senior to the Series B Preferred Stock. Voting as a single class the number of votes Mayne Pharma would have if the Series B Preferred Stock were converted into . Redemption for a price per share equal to the Per Share Price plus any accrued but unpaid dividends on such shares. However, pursuant to the Amended and Restated COD, the redemption rights were removed. Terms of the Warrants The Warrants are divided equally between the Series A Warrants and the Series B Warrants (i.e., with each being exercisable for an aggregate of 5,434,783 shares of if all Closings had occurred), which represents fifty percent ( 50 underlying the Series B Preferred Stock. The Warrants were issued, pro rata in relation to the total investment in the Series B Preferred Stock, at each Closing. The Warrants are substantially identical in form, except that: (i) the exercise price per share of the Series A Warrants shall be $0.23 per share and the exercise price per share of the Series B Warrants shall be $0.275 per share (collectively, the “Warrant Exercise Price”) and (ii) The Series A Warrants shall have a term of two (2) years from the date of issuance and the Series B Warrants shall have term of five (5) years from the date of issuance. The Warrant Exercise Price shall be subject to customary stock-based, but not price-based, anti-dilution protection. The Warrants will not be eligible for “cashless” exercise.

Liquidity and management's plan

Liquidity and management's plans	12 Months Ended
	Dec. 31, 2018
Text Block [Abstract]
Liquidity and management's plans	2. Liquidity and management’s plans: At December 31, 2018, the Company had approximately $1.1 million in cash and cash equivalents. In December 2018, the Company entered into an agreement with Mayne Pharma which will provide $3.0 million in funding by June 30, 2019 and up to an additional $2.0 million if certain conditions are met as discussed in Note 1 above. Based on the Company’s current operational plan and budget, the Company expects that it has sufficient cash to manage its business into approximately the third quarter of 2020. This estimation assumes the Company does not accelerate the development of existing product candidates, acquire other drug development opportunities, or otherwise face unexpected events, costs or contingencies, any of which could affect the Company’s cash requirements. Available resources may be consumed more rapidly than anticipated, potentially resulting in the need for additional funding. The Company intends to finance additional research and development, commercialization and distribution efforts, and its working capital needs primarily through the following: • Proceeds from public and private financings (including, most recently, financings from the Company’s majority shareholder, Mayne Pharma) and, potentially, from strategic transactions; • advances from Mayne Pharma of potential future royalties on the SUBA-Itraconazole BCCNS product available under the Third Amended SLA; • royalty revenue from Mayne Pharma from sales of SUBA-Itraconazole BCCNS upon approval by FDA (after earned royalties have been applied to any advances due under the Third Amended SLA) • proceeds from the exercise of outstanding warrants previously issued in private financings (including, potentially, warrants held by our majority shareholder, Mayne Pharma); • potential partnerships with other pharmaceutical companies to assist in the supply, manufacturing and distribution of our products for which we would expect to receive milestone and royalty payments; • potential licensing and joint venture arrangements with third parties, including other pharmaceutical companies where we would receive funding based on out-licensing our product; and • seeking government or private foundation grants which would be awarded to us to further develop our current and future anti-cancer therapies. However, there is a risk that none of these plans will be implemented in a manner necessary to sustain the Company for an extended period of time and that the Company will be unable to obtain additional financing when needed on commercially reasonable terms, if at all. If adequate funds are not available when needed, the Company may be required to significantly reduce or refocus operations or to obtain funds through arrangements that may require the Company to relinquish rights to technologies or potential markets, any of which could have a material adverse effect on the Company

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies: Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” which supersedes the revenue recognition requirements of Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition” and most industry-specific guidance on revenue recognition throughout the ASC. The new standard is principles-based and provides a five-step model to determine when and how revenue is recognized. The core principle of the new standard is that revenue should be recognized when a company transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also requires disclosure of qualitative and quantitative information surrounding the amount, nature, timing and uncertainty of revenues and cash flows arising from contracts with customers. The new standard, as updated in 2015, will be effective for the Company in the first quarter for the year ending December 31, 2018 and can be applied either retrospectively to all periods presented or as a cumulative-effect adjustment as of the date of adoption. Early adoption is not permitted. The Company will evaluate the impact of adoption of the new standard on its financial statements upon commencement of revenue generating activities. In April 2016, the FASB issued ASU 2016-10, “ Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing.” ASU 2016-10 clarifies the implementation guidance on identifying performance obligations. These ASUs apply to all companies that enter into contracts with customers to transfer goods or services. This ASUs is effective for public entities for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted, but not before interim and annual reporting periods beginning after December 15, 2016. Entities have the choice to apply the ASUs either retrospectively to each reporting period presented or by recognizing the cumulative effect of applying these standards at the date of initial application and not adjusting comparative information. The Company will evaluate the impact of adoption of the new standard on its financial statements upon commencement of revenue generating activities. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting , which amends Accounting Standards Codification (“ASC”) Topic 718, Compensation – Stock Compensation. ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and early adoption is permitted. The Company evaluated the impact of the revised guidance on its financial statements and determined it had no significant impact. Management has considered all other recent accounting pronouncements that are issued, but not effective, and it does not believe that they will have a significant impact on the Company’s Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Revenue Recognition The Company currently has no ongoing source of revenues. Miscellaneous income, including interest, is recognized when earned by the Company. Deferred revenue represents cash received for royalties in advance of being earned. Such payments are reflected as deferred revenue until recognized under the Company’s revenue recognition policy. Deferred revenue would be classified as current if management believes the Company will be able to recognize the deferred amount as revenue within twelve months of the balance sheet date. Deferred revenue will be recognized when the product is sold and the royalty is earned. Since all deferred revenue is related to the BCCNS product which is yet to be approved by FDA, the Company has determined that 100% of the advances of the royalty received by Mayne Pharma should be classified as non-current. At December 31, 2018, Deferred Revenue consisted of $0.5 million of royalties advanced by Mayne Pharma under the Third Amended SLA. There was no Deferred Revenue at December 31, 2017. Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts of $250,000 for substantially all accounts. As of December 31, 2018, the Company had approximately $0.8 million in excess of the amount covered by Federal Deposit Insurance Corporation with one financial institution. Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company as well as purchased in-process research and development. Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employees using Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 – Accounting for Share-Based Payments, which provides for the use of the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. Fair values of restricted stock units issued are determined by the Company based predominantly on the trading price of the common stock on the date of grant. Fair value of each common stock option is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on historical volatility of a peer group’s common stock and other factors estimated over the expected term of the options. The expected term of the options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield. In applying the Black-Scholes option pricing model for options issued in March 2018 that vested on the grant date, the assumptions were as follows: expected price volatility of 113.67%; risk-free interest rate of 2.64%; weighted average expected life in years of 5; and no dividend yield. 116.59%; risk-free interest rate of 2.64%; weighted average expected life in years of 6; and no dividend yield. In applying the Black-Scholes option pricing model for options issued in June 2018 that will vest on the anniversary of the grant date, the assumptions were as follows: expected price volatility of 112.6%; risk-free interest rate of 2.81%; weighted average expected life in years of 6; and no dividend yield. The value of these awards is based upon their grant-date fair value. That cost is recognized over the period during which the employee is required to provide service in exchange for the award. Income taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. See Note 4 for details. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the financial statements for the years ended December 31, 2018 or 2017.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	4. Income Taxes: The difference between expected income tax benefits and income tax benefit recorded in the financial statements is explained below: December 31, 2018 2017 Income taxes benefit computed at statutory rate $ (955,548 ) $ (1,734,396 ) State income tax benefit, net (188,002 ) (176,082 ) Change in effective tax rate — 2,701,758 Other (24,357 ) (369,400 ) Change in valuation allowance 1,167,907 (421,880 ) Total $ — $ — The significant components of deferred income tax assets and liabilities consist of the following: December 31, Deferred tax assets (liabilities) 2018 2017 In-process research and development $ 736,325 $ 736,325 Net operating loss carry forward 5,807,112 4,759,727 R&D credit 310,682 211,461 Share-based compensation 33,943 9,424 Other 2,607 5,825 6,890,669 5,722,762 Less: valuation allowance (6,890,669 ) (5,722,762 ) Total $ — $ — In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized. At December 31, 2018 and 2017, the Company recorded a 100% valuation allowance against its deferred tax assets as it has determined such amounts will not be currently realizable. The Company has a federal net operating loss (“NOLs”) of approximately $23.1 million as of December 31, 2018. Under Section 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a “loss corporation”, as defined, there are annual limitations on the amount of the NOLs and other deductions which are available to the Company. The portion of the NOLs incurred prior to August 12, 2013 is subject to this limitation. As such, the use of these NOLs to offset taxable income is limited to approximately $35,000 per year and the Company has written off the deferred tax assets associated with the NOLs limited due to the ownership change that occurred on August 12, 2013. The Company’s State NOLS are approximately $23.1 million as of December 31, 2018. The loss carryforwards began to expire in 2018.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Federal Home Loan Banks [Abstract]
Stockholders' Equity	5. Stockholders’ Equity: Employee Stock Plans A 2009 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders of CBI. There are no options outstanding under this plan. On July 18, 2014, the EIP was adopted by the Company’s Board of Directors. On September 30, 2014, the EIP was approved by the majority of stockholders. The 2014 EIP initially authorized the issuance of up to 32,583,475 shares of the Company’s common stock. An additional 11 million shares were added to the 2014 EIP for a total of 43,583,475 shares pursuant to the Agreement entered into by the Company and Mayne Pharma in December 2018. All previously outstanding RSUs vested upon the change in control as a result of Mayne Pharma’s November 2016 warrant exercise, in connection with which Mayne Pharma became the Company’s majority stockholder. On March 8, 2017, 26,541,738 previously vested but unpaid RSUs were settled by issuing shares of common stock. Upon settlement of the RSUs, the Company issued 15,739,594 shares of common stock to employees (including executive officers), current and former Board members, and contractors. Additionally, 10,802,144 shares of common stock, valued at approximately $3.7 million, were withheld from issuance representing estimated income taxes due from the RSU recipients as the fair value of the shares is considered taxable income upon issuance. The Company subsequently remitted to the appropriate taxing authorities in cash both the Company’s tax withholdings and the RSU recipient portions of the tax withholdings in the amount of approximately $3.7 million. Stock option activity for the years ended December 31, 2017 and 2018 is as follows: Weighted Average Aggreate Number of Exercise Price Intrinsic Shares Per Share Value Outstanding at January 1, 2017 650,000 $ 0.24 $ 97,500 No activity in 2017 — — Outstanding at December 31, 2017 650,000 $ 0.24 $ 6,500 Granted to Directors and Officers in 2018 2,774,000 $ 0.29 Exercised — — Forfeited — — Outstanding at December 31, 2018 3,424,000 $ 0.28 $ 0 Options outstanding at December 31, 2018 are as follows: Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Weighted Average Exercise Price Aggregate Intrinsic Value $ 0.20 - $ 0.25 650,000 7.50 $ 0.24 $ 0 $ 0.26 - $ 0.30 1,862,000 9.21 $ 0.27 $ 0 $ 0.30 - $ 0.33 912,000 9.46 $ 0.33 $ 0 3,424,000 $ 0 Options exercisable at December 31, 2018 are as follows: Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Weighted Average Exercise Price Aggregate Intrinsic Value $ 0.20 - $ 0.25 650,000 7.50 $ 0.24 $ 0 $ 0.26 - $ 0.30 758,000 9.21 $ 0.27 $ 0 1,408,000 $ 0 The weighted average grant date fair value of options granted during the year ended December 31, 2018 was $0.24. There were no options granted during the year ended December 31, 2017. Non-vested stock option activity for the year ended December 31, 2018 is as follows: Weighted Average Aggreate Number of Exercise Price Intrinsic Shares Per Share Value Non-vested at December 31, 2017 — Granted 2,774,000 Vested (758,000 ) Forfeited — Non-vested at December 31, 2018 2,016,000 $ 0.25 $ 0 Incentive awards may be in the form of stock options, restricted stock, restricted stock units and performance and other awards. In the case of incentive stock options, the exercise price will not be less than 100% of the fair market value of shares covered at the time of the grant, or 110% for incentive stock options granted to persons who own more than 10% of the Company’s voting stock. Options granted will generally vest over a three-year period from the date of grant and will be exercisable for ten years, except that the term may not exceed five years for incentive stock options granted to persons who own more than 10% of the Company’s outstanding common stock. Stock-based compensation expense is determined based on the fair value of the stock-based awards and recognized over the vesting period. The Company recognized $543,089 and $1,865,993 in stock-based compensation expense related to stock options for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, there was unamortized stock-based compensation of approximately $0.1 million. Preferred Stock Issuances See Note 1 for discussion of preferred stock issued to Mayne Pharma in 2018. Warrants See Note 1 for discussion of warrants issued in conjunction with the Mayne Pharma Purchase Agreement. See Note 1 for discussion of the warrants issued in connection with the Series B Preferred Stock Purchase Agreement. Details of the 2017 and 2018 warrant exercises can be found in the chart below: # of Warrants Exercise Total Year Warrant Holder Exercised Price Proceeds 2017 May 2016 Financing Investors 412,500 $ 0.12 $ 49,500 2018 May 2016 Financing Investors 100,000 $ 0.12 $ 12,000 There were 64,868,959 outstanding common stock warrants at December 31, 2018 with a weighted average exercise price of $0.13 and a weighted average remaining life of 2.1 years.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	6. Related party transactions: The Company has significant contractual agreements with majority stockholder Mayne Pharma as discussed in Note 1 and Note 3. There were no amounts due to or from Mayne Pharma at December 31, 2018.

Legal Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	7. Legal Proceedings: The Company is currently not subject to any material legal proceedings. However, the Company may from time to time become a party to various legal proceedings arising in the ordinary course of business.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events: In January 2019, the Company entered into a 6-month lease for office space in Tampa, Florida related to the relocation of their corporate office beginning February 1, 2019. The monthly rent payment beginning February 1, 2019 is $3,511. On January 15, 2019, the Company issued 362,121 shares of common stock to Mayne Pharma in payment of the Series B Preferred Stock dividend for the period of July 1, 2018 through December 31, 2018.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Recent accounting pronouncements	Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” which supersedes the revenue recognition requirements of Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition” and most industry-specific guidance on revenue recognition throughout the ASC. The new standard is principles-based and provides a five-step model to determine when and how revenue is recognized. The core principle of the new standard is that revenue should be recognized when a company transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also requires disclosure of qualitative and quantitative information surrounding the amount, nature, timing and uncertainty of revenues and cash flows arising from contracts with customers. The new standard, as updated in 2015, will be effective for the Company in the first quarter for the year ending December 31, 2018 and can be applied either retrospectively to all periods presented or as a cumulative-effect adjustment as of the date of adoption. Early adoption is not permitted. The Company will evaluate the impact of adoption of the new standard on its financial statements upon commencement of revenue generating activities. In April 2016, the FASB issued ASU 2016-10, “ Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing.” ASU 2016-10 clarifies the implementation guidance on identifying performance obligations. These ASUs apply to all companies that enter into contracts with customers to transfer goods or services. This ASUs is effective for public entities for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted, but not before interim and annual reporting periods beginning after December 15, 2016. Entities have the choice to apply the ASUs either retrospectively to each reporting period presented or by recognizing the cumulative effect of applying these standards at the date of initial application and not adjusting comparative information. The Company will evaluate the impact of adoption of the new standard on its financial statements upon commencement of revenue generating activities. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting , which amends Accounting Standards Codification (“ASC”) Topic 718, Compensation – Stock Compensation. ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and early adoption is permitted. The Company evaluated the impact of the revised guidance on its financial statements and determined it had no significant impact. Management has considered all other recent accounting pronouncements that are issued, but not effective, and it does not believe that they will have a significant impact on the Company’s
Estimates	Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition The Company currently has no ongoing source of revenues. Miscellaneous income, including interest, is recognized when earned by the Company. Deferred revenue represents cash received for royalties in advance of being earned. Such payments are reflected as deferred revenue until recognized under the Company’s revenue recognition policy. Deferred revenue would be classified as current if management believes the Company will be able to recognize the deferred amount as revenue within twelve months of the balance sheet date. Deferred revenue will be recognized when the product is sold and the royalty is earned. Since all deferred revenue is related to the BCCNS product which is yet to be approved by FDA, the Company has determined that 100% of the advances of the royalty received by Mayne Pharma should be classified as non-current. At December 31, 2018, Deferred Revenue consisted of $0.5 million of royalties advanced by Mayne Pharma under the Third Amended SLA. There was no Deferred Revenue at December 31, 2017.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts of $250,000 for substantially all accounts. As of December 31, 2018, the Company had approximately $0.8 million in excess of the amount covered by Federal Deposit Insurance Corporation with one financial institution.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company as well as purchased in-process research and development.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employees using Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 – Accounting for Share-Based Payments, which provides for the use of the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. Fair values of restricted stock units issued are determined by the Company based predominantly on the trading price of the common stock on the date of grant. Fair value of each common stock option is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on historical volatility of a peer group’s common stock and other factors estimated over the expected term of the options. The expected term of the options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield. In applying the Black-Scholes option pricing model for options issued in March 2018 that vested on the grant date, the assumptions were as follows: expected price volatility of 113.67%; risk-free interest rate of 2.64%; weighted average expected life in years of 5; and no dividend yield. 116.59%; risk-free interest rate of 2.64%; weighted average expected life in years of 6; and no dividend yield. In applying the Black-Scholes option pricing model for options issued in June 2018 that will vest on the anniversary of the grant date, the assumptions were as follows: expected price volatility of 112.6%; risk-free interest rate of 2.81%; weighted average expected life in years of 6; and no dividend yield. The value of these awards is based upon their grant-date fair value. That cost is recognized over the period during which the employee is required to provide service in exchange for the award.
Income taxes	Income taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. See Note 4 for details. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the financial statements for the years ended December 31, 2018 or 2017.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Difference Between Expected Income Tax Benefits and Income Tax Benefit Recorded in the Financial Statements	The difference between expected income tax benefits and income tax benefit recorded in the financial statements is explained below: December 31, 2018 2017 Income taxes benefit computed at statutory rate $ (955,548 ) $ (1,734,396 ) State income tax benefit, net (188,002 ) (176,082 ) Change in effective tax rate — 2,701,758 Other (24,357 ) (369,400 ) Change in valuation allowance 1,167,907 (421,880 ) Total $ — $ —
Components of Deferred Income Tax Assets and Liabilities	The significant components of deferred income tax assets and liabilities consist of the following: December 31, Deferred tax assets (liabilities) 2018 2017 In-process research and development $ 736,325 $ 736,325 Net operating loss carry forward 5,807,112 4,759,727 R&D credit 310,682 211,461 Share-based compensation 33,943 9,424 Other 2,607 5,825 6,890,669 5,722,762 Less: valuation allowance (6,890,669 ) (5,722,762 ) Total $ — $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Federal Home Loan Banks [Abstract]
Schedule of Stock Option Activity	Stock option activity for the years ended December 31, 2017 and 2018 is as follows: Weighted Average Aggreate Number of Exercise Price Intrinsic Shares Per Share Value Outstanding at January 1, 2017 650,000 $ 0.24 $ 97,500 No activity in 2017 — — Outstanding at December 31, 2017 650,000 $ 0.24 $ 6,500 Granted to Directors and Officers in 2018 2,774,000 $ 0.29 Exercised — — Forfeited — — Outstanding at December 31, 2018 3,424,000 $ 0.28 $ 0
Information Regarding Stock Options Outstanding and Exercisable	Options outstanding at December 31, 2018 are as follows: Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Weighted Average Exercise Price Aggregate Intrinsic Value $ 0.20 - $ 0.25 650,000 7.50 $ 0.24 $ 0 $ 0.26 - $ 0.30 1,862,000 9.21 $ 0.27 $ 0 $ 0.30 - $ 0.33 912,000 9.46 $ 0.33 $ 0 3,424,000 $ 0 Options exercisable at December 31, 2018 are as follows: Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Weighted Average Exercise Price Aggregate Intrinsic Value $ 0.20 - $ 0.25 650,000 7.50 $ 0.24 $ 0 $ 0.26 - $ 0.30 758,000 9.21 $ 0.27 $ 0 1,408,000 $ 0
Summary of Non-vested Stock Option Activity	Non-vested stock option activity for the year ended December 31, 2018 is as follows: Weighted Average Aggreate Number of Exercise Price Intrinsic Shares Per Share Value Non-vested at December 31, 2017 — Granted 2,774,000 Vested (758,000 ) Forfeited — Non-vested at December 31, 2018 2,016,000 $ 0.25 $ 0
Summary of Warrant Exercises	Details of the 2017 and 2018 warrant exercises can be found in the chart below: # of Warrants Exercise Total Year Warrant Holder Exercised Price Proceeds 2017 May 2016 Financing Investors 412,500 $ 0.12 $ 49,500 2018 May 2016 Financing Investors 100,000 $ 0.12 $ 12,000

Corporate Overview - Additional

Corporate Overview - Additional Information (Detail)	Jul. 31, 2018USD ($)	Jan. 10, 2018USD ($)	Jan. 08, 2018USD ($)$ / sharesshares	Dec. 31, 2018USD ($)Conversion$ / sharesshares	Dec. 18, 2018USD ($)	Dec. 31, 2017$ / sharesshares
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, par value | $ / shares				$ 0.0001		$ 0.0001
Preferred stock, shares outstanding				0		0
Royalty rate on future net sales				9.00%
Description of royalty payment				With respect to each Advance made by Mayne Pharma prior to the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.75 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company, and with respect to each Advance made by Mayne Pharma following the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.85 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company.​​​​​​​
Fair value inputs value royalty rate				70.00%
Series B Convertible Redeemable Preferred Stock [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Preferred stock, shares outstanding				5,797,102
Series A Warrants [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Warrants issued to purchase common stock			4,347,827
Series B Warrants [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Warrants issued to purchase common stock			4,347,827
Securities Purchase Agreement [Member] | Series B Preferred Stock [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shares issued, price per share | $ / shares				$ 0.69
Shares issued, price per share | Conversion				3
Mayne Pharma [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Voting right percentage				50.00%
Consideration in advance funds of clinical data and regulatory rights | $				$ 5,000,000	$ 500,000
Gross proceeds from sale of new common stock, preferred stock equity subordinate | $ | $				$ 3,000,000
Mayne Pharma [Member] | Equity Incentive Plan [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shares authorized to be issued				6,624,000
Number of shares of common stock issued				17,624,000
Mayne Pharma [Member] | Equity Incentive Plan [Member] | 2014 [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Increase in equity incentive plan				11,000,000
Shares authorized to be issued				32,583,475
Number of shares of common stock issued				43,583,475
Mayne Pharma [Member] | Upon Fda Approval [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Consideration in advance funds of clinical data and regulatory rights | $				$ 1,500,000
Mayne Pharma [Member] | SUBA Itraconazole BCCNS [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Consideration in advance funds of clinical data and regulatory rights | $				1,000,000
Mayne Pharma [Member] | HPPI [Member] | Available-for-sale Securities [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Consideration in advance funds of clinical data and regulatory rights | $				$ 2,000,000
Mayne Pharma [Member] | Series B Convertible Redeemable Preferred Stock [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Preferred stock, shares outstanding			5,797,102
Mayne Pharma [Member] | Securities Purchase Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of warrant coverage on shares of Common Stock			50.00%
Purchase Agreement, potential gross proceeds | $			$ 5,000,000
Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Series B Preferred Stock [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Preferred stock convertible to common stock			17,391,306
Purchase Agreement, price per share of preferred stock to be issued | $ / shares			$ 0.69
Preferred stock dividend rate percentage			5.00%
Dividends payable nature				Dividends are paid semi-annually as of June 30 (with a payment date of July 15) and December 31 (with a payment date of January 15) each year. The Company has the option in its discretion to pay dividends in cash or shares of Common Stock. If the Company elects to pay dividends in shares of Common Stock, the number of shares to be paid being calculated by dividing (i) the principal value of the dividend to be paid by (ii) the 6-month volume-weighted average price of the Common Stock prior to the measurement date (being 31 December, or 30 June) of the applicable year.
Conversion price per share | $ / shares			$ 0.23
Purchase Agreement, preferred stock to be issued			7,246,377
Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Minimum [Member] | Series B Preferred Stock [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Purchase Agreement, redemption period			5 years
Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Purchase Agreement, price per share of preferred stock to be issued | $ / shares			$ 0.23
Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Series A Warrants [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Warrant expiration period			2 years
Exercise price of warrants | $ / shares			$ 0.23
Warrants issued to purchase common stock			5,434,783
Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Series B Warrants [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Warrant expiration period			5 years
Exercise price of warrants | $ / shares			$ 0.275
Warrants issued to purchase common stock			5,434,783
Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Initial Closing [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Gross proceeds from sale of new common stock, preferred stock equity subordinate | $ | $		$ 2,400,000
Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Second Closing [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Gross proceeds from sale of new common stock, preferred stock equity subordinate | $ | $	$ 1,600,000
Mayne Pharma [Member] | Securities Purchase Agreement [Member] | Third Closing [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Purchase Agreement, potential gross proceeds | $				$ 1,000,000

Liquidity and Management's Pl_2

Liquidity and Management's Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 18, 2018	Dec. 31, 2017	Dec. 31, 2016
Bankruptcy [Line Items]
Cash and cash equivalents	$ 1,108,713		$ 344,113	$ 6,885,422
Mayne Pharma [Member]
Bankruptcy [Line Items]
Gross proceeds from sale of new common stock, preferred stock equity subordinate | $	3,000,000
Consideration in advance funds of clinical data and regulatory rights	5,000,000	$ 500,000
Mayne Pharma [Member] | Available-for-sale Securities [Member] | HPPI [Member]
Bankruptcy [Line Items]
Consideration in advance funds of clinical data and regulatory rights	$ 2,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	1 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Line Items]
Cash, FDIC insured amount			$ 250,000
Cash balance in excess of amount covered by Federal Deposit Insurance Corporation			800,000
Deferred revenue				$ 0
Royalty [Member]
Accounting Policies [Line Items]
Deferred revenue			$ 500,000
Black-Scholes Option Pricing Model [Member] | Options vesting grant date [Member]
Accounting Policies [Line Items]
Volatility rate		113.67%
Risk-free interest rate		2.64%
Weighted average expected life (in years)		5 years
Dividend yield		0.00%
Black-Scholes Option Pricing Model [Member] | Options vesting on first anniversary of grant date [Member]
Accounting Policies [Line Items]
Volatility rate	112.60%	116.59%
Risk-free interest rate	2.81%	2.64%
Weighted average expected life (in years)	6 years	6 years
Dividend yield	0.00%	0.00%

Income Taxes - The Difference B

Income Taxes - The Difference Between Expected Income Tax Benefits and Income Tax Benefit Recorded in The Financial Statements (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income taxes benefit computed at statutory rate	$ (955,548)	$ (1,734,396)
State income tax benefit, net	(188,002)	(176,082)
Change in effective tax rate		2,701,758
Other	(24,357)	(369,400)
Change in valuation allowance	1,167,907	(421,880)
Expected income tax benefits and income tax benefits recorded	$ 0	$ 0

Income Taxes - Components of De

Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
In-process research and development	$ 736,325	$ 736,325
Net operating loss carry forward	5,807,112	4,759,727
R&D credit	310,682	211,461
Share-based compensation	33,943	9,424
Other	2,607	5,825
Deferred tax assets gross	6,890,669	5,722,762
Less: valuation allowance	(6,890,669)	(5,722,762)
Deferred tax assets, net	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
Percentage of valuation allowance against deferred tax assets	100.00%	100.00%
Valuation Allowance, Methodologies and Assumptions	In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized.
NOLs used to offset taxable income	$ 35,000
Minimum [Member]
Income Taxes [Line Items]
Valuation Allowance, Assumption Percentage	50.00%	50.00%
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Net operating loss carryforward	$ 23,100,000
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Net operating loss carryforward	$ 23,100,000
Operating loss carryforward expiration period	Dec. 31, 2018

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Mar. 08, 2017	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense related to Restricted Stock Units and stock options		$ 543,098	$ 1,865,993
Number of outstanding common stock warrants		64,868,959
Weighted average exercise price of outstanding common stock warrants		$ 0.13
Weighted average remaining life of outstanding common stock warrants		2 years 1 month 6 days
Weighted average grant date fair value of options granted		$ 0.24	$ 0
RSUs vested		758,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares issued to employees including company's executive officers, current and former Board members, and contractors in associated with vested RSUs	15,739,594
Common shares withheld from issuance representing estimated income taxes	10,802,144
Total stock based compensation expense related to Restricted Stock Units and stock options		$ 543,089	$ 1,865,993
Unamortized stock-based compensation cost related to unpaid RSUs		$ 100,000
RSUs vested	26,541,738
Shares withheld from issuance representing estimated income taxes, value	$ 3,700,000
RSU recipient portions of tax withholdings in amount	$ 3,700,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted vesting period		3 years
Period during which options are exercisable		10 years
Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price as percentage of fair market value of shares		100.00%
More Than 10% Common Stock Owners [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price as percentage of fair market value of shares		110.00%
Minimum percentage of the company's voting stock ownership for 110% exercise price of stock options		10.00%
More Than 10% Common Stock Owners [Member] | Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period during which options are exercisable		5 years
Two Thousand Fourteen Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized to be issued under Equity Incentive Plan		32,583,475
Two Thousand Fourteen Equity Incentive Plan [Member] | Mayne Pharma [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option awards		43,583,475
Stock options awarded, Shares		11

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, Beginning Balance	650,000	650,000
Number of Shares, Exercised	0
Number of Shares, Forfeitures	0
Number of Shares, Outstanding, Ending Balance	3,424,000	650,000
Weighted Average Exercise Price per Share, Outstanding, Beginning Balance	$ 0.24	$ 0.24
Weighted Average Exercise Price per Share, Exercised	0
Weighted Average Exercise Price per Share, Forfeitures	0
Weighted Average Exercise Price per Share, Outstanding, Ending Balance	$ 0.28	$ 0.24
Aggregate Intrinsic Value, Beginning Balance	$ 0	$ 6,500	$ 97,500
Aggregate Intrinsic Value, Granted		$ 0
Aggregate Intrinsic Value, Forfeitures	0
Aggregate Intrinsic Value, Exercised	$ 0
Directors and Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	2,774,000
Weighted Average Exercise Price per Share, Granted	$ 0.29
Aggregate Intrinsic Value, Granted	$ 0

Stockholders' Equity - Informat

Stockholders' Equity - Information Regarding Stock Options Outstanding and Exercisable (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number Outstanding	3,424,000	650,000	650,000
Weighted Average Exercise Price	$ 0.28	$ 0.24	$ 0.24
Aggregate Intrinsic Value	$ 0
Number Outstanding	1,408,000
Aggregate Intrinsic Value	$ 0
Range 01 [Member]
Range of Exercise Prices	$ 0.20
Range of Exercise Prices	$ 0.25
Number Outstanding	650,000
Weighted Average Remaining Contractual Life (Years)	7 years 6 months
Weighted Average Exercise Price	$ 0.24
Aggregate Intrinsic Value	$ 0
Range of Exercise Prices	$ 0.20
Range of Exercise Prices	$ 0.25
Number Outstanding	650,000
Weighted Average Remaining Contractual Life (Years)	7 years 6 months
Weighted Average Exercise Price	$ 0.24
Aggregate Intrinsic Value	$ 0
Range 02 [Member]
Range of Exercise Prices	$ 0.26
Range of Exercise Prices	$ 0.30
Number Outstanding	1,862,000
Weighted Average Remaining Contractual Life (Years)	9 years 2 months 15 days
Weighted Average Exercise Price	$ 0.27
Aggregate Intrinsic Value	$ 0
Range of Exercise Prices	$ 0.26
Range of Exercise Prices	$ 0.30
Number Outstanding	758,000
Weighted Average Remaining Contractual Life (Years)	9 years 2 months 15 days
Weighted Average Exercise Price	$ 0.27
Aggregate Intrinsic Value	$ 0
Range 03 [Member]
Range of Exercise Prices	$ 0.30
Range of Exercise Prices	$ 0.33
Number Outstanding	912,000
Weighted Average Remaining Contractual Life (Years)	9 years 5 months 15 days
Weighted Average Exercise Price	$ 0.33
Aggregate Intrinsic Value	$ 0

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Non-vested Stock Option Activity (Detail)	12 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Abstract]
Granted	2,774,000
Vested	(758,000)
Forfeited	0
Non-vested at December 31, 2018	2,016,000
Non-vested at December 31, 2018 | $ / shares	$ 0.25
Non-vested at December 31, 2018 | $	$ 0

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Warrant Exercises (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Class of Warrant or Right [Line Items]
Total Proceeds	$ 12,000	$ 49,500
May 2016 Financing Investors [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	100,000	412,500
Exercise Price	$ 0.12	$ 0.12
Total Proceeds	$ 12,000	$ 49,500

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Mayne Pharma [Member]	Dec. 31, 2018USD ($)
Related Party Transaction [Line Items]
Due to Mayne Pharma	$ 0
Due from Mayne Pharma	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - USD ($)	Jan. 15, 2019	Jan. 31, 2019
Subsequent Event [Line Items]
Rent expense		$ 3,511
Mayne Pharma Ventures Pty LTD [Member]
Subsequent Event [Line Items]
Stock issued as a dividened	362,121